Companies Definium Therapeutics
Definium Therapeutics (DFTX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Definium Therapeutics’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers93rd pct.Of 19 peer CEOs
CEO pay, last three years
- $2,143,133FY2023
- $2,669,010FY2024
- $12,767,442FY2025
CEO total pay was $12,767,442 in fiscal 2025, up from $2,669,010 in fiscal 2024.
FY2025: salary $655,000 · bonus $0 · stock awards $11,719,750 · option awards $0
Executives and directors
Frequently asked questions
Who was the highest-paid executive at Definium Therapeutics in fiscal 2025?
As disclosed, Robert Barrow (Chief Executive Officer) was the highest-paid executive at Definium Therapeutics in fiscal 2025, with total compensation of $12,767,442.
How does Definium Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Robert Barrow's total compensation ranked at the 93rd percentile of Definium Therapeutics's disclosed peer group.
How much does Definium Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Definium Therapeutics reported total board compensation of $356,000 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Robert Barrow | $655,000 | $0 | $11,719,750 | $0 | $378,263 | $0 | $14,429 | $12,767,442 |
| Chief Executive Officer | ||||||||
| Brandi Roberts | 288,750 | 0 | 1,815,000 | 2,890,889 | 121,322 | 0 | 401 | 5,116,362 |
| Chief Financial Officer | ||||||||
| Daniel Karlin | 510,000 | 0 | 3,262,525 | 0 | 214,200 | 0 | 14,533 | 4,001,258 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Robert Barrow | $12,767,442 | $2,669,010 | $2,143,133 | ↑ +10,098,432 |
| Brandi Roberts | 5,116,362 | — | — | — |
| Daniel Karlin | 4,001,258 | 1,330,319 | 1,037,272 | ↑ +2,670,939 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Daniel Karlin | RSU | 3,958 | — | $52,998 |
| Daniel Karlin | Option | 5,208 | 17.72 | — |
| Robert Barrow | RSU | 7,583 | — | 101,536 |
| Robert Barrow | Option | 12,125 | 17.72 | — |
| Daniel Karlin | RSU | 39,063 | — | 523,054 |
| Brandi Roberts | RSU | 62,500 | — | 836,875 |
| Daniel Karlin | Option | 81,250 | 4.98 | — |
| Daniel Karlin | RSU | 93,438 | — | 1,251,135 |
| Daniel Karlin | RSU | 100,000 | — | 1,339,000 |
| Robert Barrow | RSU | 125,000 | — | 1,673,750 |
| Robert Barrow | Option | 216,667 | 4.98 | — |
| Robert Barrow | RSU | 284,375 | — | 3,807,781 |
| Robert Barrow | RSU | 375,000 | — | 5,021,250 |
| Brandi Roberts | Option | 500,000 | 7.26 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Carol A. ValloneIndependent · Board Chair · Audit · Compensation | $97,000 | $0 | $399,827 | — | $0 | $496,827 |
| Andreas KrebsIndependent · Audit · Nominating and Corporate Governance | 85,000 | 0 | 399,827 | — | 0 | 484,827 |
| David GryskaIndependent · Audit (Chair) | 59,000 | 0 | 399,827 | — | 0 | 458,827 |
| Dr. Suzanne BruhnIndependent · Compensation (Chair) · Nominating and Corporate Governance | 58,000 | 0 | 399,827 | — | 0 | 457,827 |
| Dr. Roger CrystalIndependent · Compensation · Nominating and Corporate Governance (Chair) | 57,000 | 0 | 399,827 | — | 0 | 456,827 |
| Robert BarrowEmployee director | — | — | — | — | — | 0 |
| Roger AdsettIndependent · Newly elected | — | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $450,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $356,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $356,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Definium Therapeutics as a peer
Companies that benchmark against DFTX
No companies currently name DFTX as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ALCT Alector, Inc.KALV Kalvista Pharmaceuticals, Inc.ATAI AtaiBeckley Inc.PRAX Praxis Precision Medicines, Inc.NEUM Neumora Therapeutics, Inc.LCTX Lineage Cell Therapeutics, Inc.SLDB Solid Biosciences Inc.ARVN Arvinas, Inc.MGTX MeiraGTx Holdings plcLMRM Larimar Therapeutics, Inc.FULC Fulcrum Therapeutics, Inc.RLMD Relmada Therapeutics, Inc.AXON Annexon, Inc.CMPX Compass Pathways plcSTOK Stoke Therapeutics, Inc.ANVS Anavex Life Sciences CorpTRVI Trevi Therapeutics, Inc.LEON LeonaBio, Inc. (f/k/a Athira Pharma)HUMA Humacyte, Inc.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Stoke Therapeutics, Inc. | 2025 | Ian Smith | $170,625 | $11,590,000 | $14,035,067 | $0 | $27,031,655 |
| 2 | Definium Therapeutics | 2025 | Robert Barrow | 655,000 | 11,719,750 | 0 | 378,263 | 12,767,442 |
| 3 | Relmada Therapeutics, Inc. | 2025 | Sergio Traversa | 787,787 | 0 | 4,951,301 | 0 | 8,892,633 |
| 4 | Praxis Precision Medicines, Inc. | 2025 | Marcio Souza | 659,200 | 2,368,125 | 3,691,125 | 1,483,200 | 8,708,648 |
| 5 | MeiraGTx Holdings plc | 2025 | Alexandria Forbes | 840,000 | 5,823,500 | — | — | 8,330,006 |
| 6 | Arvinas, Inc. | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 7 | Humacyte, Inc. | 2025 | Laura Niklason | 633,606 | 0 | 4,332,725 | 0 | 5,234,908 |
| 8 | Solid Biosciences Inc. | 2025 | Alexander Cumbo | 650,988 | 2,318,275 | 1,792,397 | 0 | 5,223,442 |
| 9 | Compass Pathways plc | 2025 | Thomas Schuetz | 630,000 | 0 | 4,065,000 | 0 | 5,097,150 |
| 10 | Kalvista Pharmaceuticals, Inc. | 2025 | Benjamin Palleiko | 688,272 | 3,731,160 | 0 | 0 | 5,094,999 |
| 11 | AtaiBeckley Inc. | 2025 | Srinivas Rao | 629,200 | 0 | 3,316,737 | 0 | 4,420,555 |
| 12 | Trevi Therapeutics, Inc. | 2025 | Jennifer Good | 622,382 | 0 | 2,968,260 | 0 | 3,944,892 |
| 13 | Fulcrum Therapeutics, Inc. | 2025 | Alex Sapir | 650,000 | 0 | 2,052,132 | 411,200 | 3,251,490 |
| 14 | Lineage Cell Therapeutics, Inc. | 2025 | Brian Culley | 691,800 | 0 | 882,970 | 518,900 | 2,111,170 |
| 15 | Annexon, Inc. | 2025 | Patrick Smith | 31,201 | 0 | 0 | 0 | 40,001 |
| — | Alector, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Neumora Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Larimar Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Anavex Life Sciences Corp | — | — | — | — | — | — | not in coverage universe |
| — | LeonaBio, Inc. (f/k/a Athira Pharma) | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Definium Therapeutics | not disclosed | not disclosed | not disclosed | Aon |
| Alector, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Anavex Life Sciences Corp | not disclosed | not disclosed | not disclosed | not disclosed |
| Annexon, Inc. | 135.9% | not disclosed | No | Semler Brossy |
| Arvinas, Inc. | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| AtaiBeckley Inc. | not disclosed | Option 100 | not disclosed | Radford |
| Compass Pathways plc | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| Fulcrum Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Humacyte, Inc. | 80% | not disclosed | not disclosed | Aon plc |
| Kalvista Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Larimar Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| LeonaBio, Inc. (f/k/a Athira Pharma) | not disclosed | not disclosed | not disclosed | not disclosed |
| Lineage Cell Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Anderson |
| MeiraGTx Holdings plc | not disclosed | RSU 100 | not disclosed | Total Compensation Solutions |
| Neumora Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Praxis Precision Medicines, Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| Relmada Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon Radford |
| Solid Biosciences Inc. | 100% | not disclosed | No | Radford (AON Hewitt) |
| Stoke Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Trevi Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | — | — | — | — | — |
| 2025 | 2025-06-12 | — | — | — | — | — |
| 2024 | 2024-06-10 | — | — | — | — | — |
| 2023 | 2023-06-21 | — | — | — | — | — |
| 2022 | 2022-06-01 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-11 | —a |
| 2025 | 2025-06-12 | —b |
| 2024 | 2024-06-10 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (30 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Robert Barrow. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · page 56. As printed: 12,767,442. View filing ↗
- Section 01, Brandi Roberts. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 5,116,362. View filing ↗
- Section 01, Daniel Karlin. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 4,001,258. View filing ↗
- Section 08, Carol A. Vallone. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 496,827. View filing ↗
- Section 08, Andreas Krebs. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 484,827. View filing ↗
- Section 08, David Gryska. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 458,827. View filing ↗
- Section 08, Dr. Suzanne Bruhn. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 457,827. View filing ↗
- Section 08, Dr. Roger Crystal. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 456,827. View filing ↗
- Section 08, Robert Barrow. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Roger Adsett. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: —. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-12. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-16. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-11. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 356,000 + equity 0 + all other 0 = 356,000, summed across the director compensation table rows.
- Stoke Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Stoke Therapeutics, Inc.'s own proxy. As printed: 27,031,655. View filing ↗
- Definium Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Definium Therapeutics's own proxy. As printed: 12,767,442. View filing ↗
- Relmada Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Relmada Therapeutics, Inc.'s own proxy. As printed: 8,892,633. View filing ↗
- Praxis Precision Medicines, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Praxis Precision Medicines, Inc.'s own proxy. As printed: 8,708,648. View filing ↗
- MeiraGTx Holdings plc, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in MeiraGTx Holdings plc's own proxy. As printed: 8,330,006. View filing ↗
- Arvinas, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. View filing ↗
- Humacyte, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Humacyte, Inc.'s own proxy. As printed: 5,234,908. View filing ↗
- Solid Biosciences Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Solid Biosciences Inc.'s own proxy. As printed: 5,223,442. View filing ↗
- Compass Pathways plc, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Compass Pathways plc's own proxy. As printed: 5,097,150. View filing ↗
- Kalvista Pharmaceuticals, Inc., Section 10b CEO total. 10-KT/A, filed 2026-04-30. CEO total compensation as printed in Kalvista Pharmaceuticals, Inc.'s own proxy. As printed: 5,094,999. View filing ↗
- AtaiBeckley Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in AtaiBeckley Inc.'s own proxy. As printed: 4,420,555. View filing ↗
- Trevi Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Trevi Therapeutics, Inc.'s own proxy. As printed: 3,944,892. View filing ↗
- Fulcrum Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Fulcrum Therapeutics, Inc.'s own proxy. As printed: 3,251,490. View filing ↗
- Lineage Cell Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Lineage Cell Therapeutics, Inc.'s own proxy. As printed: 2,111,170. View filing ↗
- Annexon, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Annexon, Inc.'s own proxy. As printed: 40,001. View filing ↗